A modified human ELISPOT assay to detect specific responses to primary tumor cell targets - Wikidata - wikimedia - TriplyDB

A modified human ELISPOT assay to detect specific responses to primary tumor cell targets

A modified human ELISPOT assay to detect specific responses to primary tumor cell targets

http://www.wikidata.org/entity/Q24800412

about

A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells.Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma.Therapeutic lymphoma vaccines: importance of T-cell immunity.Autologous tumor rejection in humans: trimming the myths.BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma.Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents.Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials.Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in p ELISPOT Assay for Monitoring Cytotoxic T Lymphocytes (CTL) Activity in Cancer Vaccine Clinical Trials.Resting of Cryopreserved PBMC Does Not Generally Benefit the Performance of Antigen-Specific T Cell ELISPOT Assays.Immunological monitoring of the tumor immunoenvironment for clinical trials.Improvement of IFNg ELISPOT Performance Following Overnight Resting of Frozen PBMC Samples Confirmed Through Rigorous Statistical Analysis.Autologous peripheral blood mononuclear cell recognition of autologous proliferating tumor cells in the context of a patient-specific vaccine trial.Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol.Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma.A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors.

P2860

Q24681501-5FDE8AB9-0C45-4506-9027-E035BB11382A Q28744503-68B90192-B704-49F0-BE3E-C113746EB4AD Q33619191-FF1CCE18-203C-42C6-8EB0-9F9B0DD5C556 Q34038839-C97DA8B1-1AA5-4F1A-A000-B38A07FFE9E5 Q36530231-5048495F-C416-4B9B-8E5F-1FEBD148EE1E Q36569014-8D1338AE-46C6-4D65-9785-50DB522DD996 Q36675461-C52A550B-C4DF-4A5C-9FE8-74224B324390 Q37099271-B30F5DAB-63BE-4F7E-8A00-9FF893373C3D Q37142202-0967220D-60F7-4578-B8B0-765E48315690 Q37379219-38270D0E-7278-44EF-AA68-3A739692F8FB Q37512173-52CC8D5B-B3B9-4D5D-A8AA-21DCED947277 Q37512240-0E495E06-510B-4EBB-AED1-CFDA7B040C81 Q37955680-456730D7-BC42-4849-9D46-B8967E675A94 Q41642827-7C34EFB0-E651-4659-A41B-F69D3516EAE1 Q41769866-6BC9CCF9-2981-4F0D-9532-DB43BAC11D7D Q49935482-21398641-E63C-4399-B900-502D48D5FD53 Q51989383-12E9293F-D308-4930-A8A4-AB1F685CD98C Q52579555-AAB43CF5-1C61-4B89-B9BB-317B82E1F2B2

P2860

A modified human ELISPOT assay to detect specific responses to primary tumor cell targets

http://www.wikidata.org/entity/Q24800412

description

2004 nî lūn-bûn

@nan

2004 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի մարտին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

A modified human ELISPOT assay to detect specific responses to primary tumor cell targets

@ast

A modified human ELISPOT assay to detect specific responses to primary tumor cell targets

@en

A modified human ELISPOT assay to detect specific responses to primary tumor cell targets

@nl

type

label

A modified human ELISPOT assay to detect specific responses to primary tumor cell targets

@ast

A modified human ELISPOT assay to detect specific responses to primary tumor cell targets

@en

A modified human ELISPOT assay to detect specific responses to primary tumor cell targets

@nl

prefLabel

A modified human ELISPOT assay to detect specific responses to primary tumor cell targets

@ast

A modified human ELISPOT assay to detect specific responses to primary tumor cell targets

@en

A modified human ELISPOT assay to detect specific responses to primary tumor cell targets

@nl

P1433

Q24800412-2EDBCE9F-C2A8-4A26-86B4-DC9585B974CA

P1476

Q24800412-DF746F34-32C0-4791-801E-48BE6A366192

P2093

Q24800412-0019CA0C-7E50-466B-A612-75FABA45A8D7

Q24800412-07629180-B3BE-4BF7-8E46-92BDCA58427B

Q24800412-19DD9E71-FCCB-4B99-B7BE-A5A60C60B853

Q24800412-86893D25-B17B-41EE-84FD-9867F72BDBAE

Q24800412-9C2ED874-C5C5-476A-AC10-A4F37C8644EF

Q24800412-A11A7793-2DC1-4841-9C0B-DE4AC04098FD

Q24800412-C90EA3AF-DE5D-473B-B992-C8AE2B617193

Q24800412-F0EA3596-B5D4-4B5D-B5A0-22AFE8BA76C3

P2860

Q24800412-00175DDB-2BC3-4718-855C-C1271A8CF34C

Q24800412-0DD5FF1B-B58D-4EFD-BC85-EAA78E0C5144

Q24800412-4B20C49A-AC86-4CDD-8563-751855E7CC53

Q24800412-608FE9F4-6682-473E-A64B-183B370F05DA

Q24800412-6189E2FC-EACF-4E0A-853E-D205A5A93946

Q24800412-852237DF-CF1A-4308-908E-65F5A6E11A9A

Q24800412-A09E598C-C412-4244-A460-3F5F8E655C38

Q24800412-A1435C1C-E310-440E-A27B-8EF052FE5536

Q24800412-ACACBB74-3057-4DD3-9988-39B985140D68

Q24800412-C2D33F17-2E61-4C18-9968-B8810BE30562

P2888

Q24800412-2CF85389-EF58-4043-854A-C2A343CEEBE1

P304

Q24800412-DCC45E78-84C4-46D6-92B0-6FAAA18CF74F

P31

Q24800412-35D81689-52A2-4DD7-BC96-1249F7BD95E6

P356

Q24800412-2A371F13-1637-429D-955F-6ADABD41732E

P433

Q24800412-F23D82E1-126D-4011-B868-1AADFBC5D70B

P478

Q24800412-88AAE9C3-2FC6-46B2-BB71-2B5AD591DA8A

P577

Q24800412-5A142582-81CD-4A89-9CB6-1412E7B3D5B2

P5875

Q24800412-0FC468D3-BFF7-4185-B629-BDCD961E06E5

P6179

Q24800412-2D2C5369-0B33-4052-AE85-0788BF26A640

P698

Q24800412-FBA14797-0621-44E0-8891-99291B7097C1

P932

Q24800412-87767047-0481-4649-9196-07A84AF7384E

P356

P1433

Journal of Translational Medicine

P1476

A modified human ELISPOT assay to detect specific responses to primary tumor cell targets

@en

P2093

Anatoli Malyguine

http://www.w3.org/2001/XMLSchema#string

Angela Troke

http://www.w3.org/2001/XMLSchema#string

Kimberly A Shafer-Weaver

http://www.w3.org/2001/XMLSchema#string

Larry W Kwak

http://www.w3.org/2001/XMLSchema#string

Michael Baseler

http://www.w3.org/2001/XMLSchema#string

Sattva S Neelapu

http://www.w3.org/2001/XMLSchema#string

Susan L Strobl

http://www.w3.org/2001/XMLSchema#string

Tracy Ulderich

http://www.w3.org/2001/XMLSchema#string

P2860

Human tumor antigens for cancer vaccine development.

Quantification of tumor-specific T lymphocytes with the ELISPOT assay.

Immunologic monitoring of clinical trials in patients with cancer: technology versus common sense.

Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity.

Progress in human tumour immunology and immunotherapy.

Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.

Endogenous antigen presentation by MHC class II molecules.

In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins.

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma.

Class II MHC molecules can use the endogenous pathway of antigen presentation.

P2888

P304

9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1479-5876-2-9

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2004-03-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8650957

http://www.w3.org/2001/XMLSchema#string

P6179

1029951803

http://www.w3.org/2001/XMLSchema#string

P698

15050026

http://www.w3.org/2001/XMLSchema#string

P932

415560

http://www.w3.org/2001/XMLSchema#string